Welcome to the CJU website » LOG IN


Pancreatic metastasectomy of renal cell carcinoma: a single institution experience
Department of Surgery, Mayo Clinic Florida, Jacksonville, Florida, USA
Feb  2022 (Vol.  29, Issue  1, Pages( 11020 - 11023)
PMID: 35150225


Text-Size + 

  • Introduction:

    Renal cell carcinoma (RCC) is the most common primary neoplasia that metastasizes to the pancreas. Pancreatic metastasis (PM) occur in asymptomatic older patients and are identified during follow up. If resectable, surgery is the treatment of choice for long term survival. Our goal is to analyze outcomes of patients with RCC-PM.

    Material and methods:

    We reviewed all patients with metastatic RCC (mRCC) who underwent resection, from known primary RCC and RCC-PM.


    There were 16 patients (mean age of 67 ± 8 years, male 8 (50%), mean BMI 29 ± 5.36 kg/m2). Half of them were asymptomatic. Diagnosis was incidental in 56.25% with a median lesion size of 25 mm (12-80). Pancreatic resections performed were: pancreatoduodenectomy (31.25%), distal pancreatectomy (56.25%) and total pancreatectomy (12.5%). Median estimated blood loss was 225 mL (15-2,200), median operative time was 242 min (63-420). Median length of stay was 6 days (2-30). New-onset diabetes was 6.25%. The minor complication and reoperation rates, were 37.5% and 6.25%, respectively. The median number of harvested lymph nodes was 17 (4-31), all were negative. All had a R0 resection. Recurrence of disease was 18.75% with a median time after surgery of 3 years (2-6). The median follow up was 9 years (0-15). Thirteen (81.25%) patients are still alive, eight are disease free. Three (18.75%) died.


    Long term survival can be achieved with surgical resection of PM from RCC in selected patients in whom complete resection is possible.